A practical reference on lyophilisation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
=== Distribution === With oral CPA, there is a probable distribution phase of CPA into tissues which lasts about 12 hours and has a half-life of 3 hours. CPA is very lipophilic, and it is sequestered into fat, which provides a depot effect. The volume of distribution of CPA is 20.6 ± 3.5 L/kg. CPA crosses the blood–brain barrier, which is evidenced by the suppression of gonadotropin secretion that is observed during therapy with it (the site of action of this effect being the pituitary gland, a part of the brain). In terms of plasma protein binding, CPA does not bind to SHBG or corticosteroid-binding globulin and is instead bound exclusively to albumin (93%), with the remainder (7%) circulating free or unbound. The affinity of CPA for SHBG is very low at about 0.006% of that of testosterone or DHT.
== External links == Clinical trial number NCT02896192 for "Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity" at ClinicalTrials.gov Clinical trial number NCT03287960 for "Setmelanotide for the Treatment of LEPR Deficiency Obesity" at ClinicalTrials.gov
The grave was discovered by a farmer working in a potato-field at Hillside Farm on Bryher in March 1999, when his tractor wheel sank into the ground and to free it he moved a large stone which revealed the cist. He reached into the cavity and found a sword. He contacted the British Museum who advised him to take it to the Isles of Scilly Museum, where it was identified as a La Tène II iron sword. The then Prince Charles visited the farm while on a visit to the islands in May 1999, and a project for the evaluation, recording and reinstatement of the site was undertaken jointly by Cornwall Archaeology Unit, English Heritage and the British Museum.
Sources: en.wikipedia.org
Absenta ("absinthe" in Spanish) is sometimes associated with a regional style that often differed slightly from its French cousin. Traditional absentas may taste slightly different due to their use of Alicante anise, and often exhibit a characteristic citrus flavour. Hausgemacht (German for home-made, often abbreviated as HG) refers to clandestine absinthe (not to be confused with the Swiss La Clandestine brand) that is home-distilled by hobbyists. It should not be confused with absinthe kits. Hausgemacht absinthe is produced in tiny quantities for personal use and not for the commercial market. Clandestine production increased after absinthe was banned, when small producers went underground, most notably in Switzerland. Although the ban has been lifted in Switzerland, some clandestine distillers have not legitimised their production. Authorities believe that high taxes on alcohol and the mystique of being underground are likely reasons.
== Research == Experiments using cultured cells have demonstrated that humanin has both neuroprotective as well as cytoprotective effects and experiments in rodents have found that it has protective effects in Alzheimer's disease models, Huntington's disease models and stroke models. Humanin is proposed to have myriad neuroprotective and cytoprotective effects. Studies in both cells and rodents have found that administration of humanin or humanin derivatives increases survival and/or physiological parameters in Alzheimer's disease models. In addition to Alzheimer's disease, humanin has other neuroprotective effects against models of Huntington's disease, prion disease, and stroke. Beyond the possible neuroprotective effects, humanin protects against oxidative stress, atherosclerotic plaque formation, and heart attack. Humanin activates chaperone-mediated autophagy in a dose-dependent manner. Humanin decreases production of inflammatory cytokines, which is part of its anti-apoptotic effect. Metabolic effects have also been demonstrated and humanin helps improve survival of pancreatic beta-cells, which may help with type 1 diabetes, and increases insulin sensitivity, which may help with type 2 diabetes. In rats, the humanin analog appears to normalize glucose levels and reduce diabetes symptoms. Rattin shows the same ability as humanin to defend neurons from the toxicity of beta-amyloid, associated with the degeneration in Alzheimer's disease.
Lysergic acid diethylamide, commonly known as LSD (from German Lysergsäurediethylamid) and by the nicknames acid and Lucy, is a semisynthetic psychedelic drug derived from ergot, known for its potent psychological effects. LSD taken orally has an onset of action of 0.4 to 1.0 hours and a duration of 7 to 12 hours. In recreational settings it is commonly administered via tabs of blotter paper. LSD is extremely potent, with noticeable effects at doses as low as 20 micrograms and is sometimes taken in even smaller amounts for microdosing. Despite widespread use, no fatal human overdoses have been documented. LSD is mainly used recreationally or for spiritual purposes. LSD can cause mystical experiences. LSD exerts its effects primarily through high-affinity binding to several serotonin receptors, especially the serotonin 5-HT2A receptor, and to a lesser extent dopamine and adrenergic receptors. Neuroimaging studies indicate that LSD reduces the efficacy of thalamo-cortical information filtering (producing sensory overload), decreases oscillatory power within the default mode network, and flattens hierarchical organization of large-brain activity. At higher doses, it can induce visual and auditory hallucinations, ego dissolution, and anxiety. LSD use can cause hallucinogen-induced psychotic disorder where paranoia and delusions persist beyond the initial effects of the drug. LSD may lead to persistent visual disturbances known as hallucinogen persisting perception disorder (HPPD).
Sources: en.wikipedia.org
=== Competition of beta decay types === Usually unstable nuclides are clearly either "neutron rich" or "proton rich", with the former undergoing beta decay and the latter undergoing electron capture (or more rarely, due to the higher energy requirements, positron decay). However, in a few cases of odd-proton, odd-neutron radionuclides, it may be energetically favorable for the radionuclide to decay to an even-proton, even-neutron isobar either by undergoing beta-positive or beta-negative decay. Three types of beta decay in competition are illustrated by the single isotope 6429Cu (29 protons, 35 neutrons), which has a half-life of about 12.7 hours. This isotope has one unpaired proton and one unpaired neutron, so either the proton or the neutron can decay. This particular nuclide is almost equally likely to undergo proton decay (by positron emission, 18% or by electron capture, 43%; both forming 64Ni) or neutron decay (by electron emission, 39%; forming 64Zn).
=== Signaling pathways for mast cell activation === Specific signaling pathways of mast cells in different tissues provide mechanisms by which the immune system detects and is organized to deal with potential threats. Mast cells can be stimulated to degranulate by allergens through cross-linking with immunoglobulin E receptors (e.g., FcεRI), physical injury through pattern recognition receptors for damage-associated molecular patterns (DAMPs), microbial pathogens through pattern recognition receptors for pathogen-associated molecular patterns (PAMPs), and various compounds through their associated G-protein coupled receptors (e.g., morphine through opioid receptors) or ligand-gated ion channels. Complement proteins can activate membrane receptors on mast cells to exert various functions as well.
The United States Patent Office issued a ruling 8 October 1883, that Edison's patents were based on the prior art of William Sawyer and were invalid. Litigation continued for a number of years. Eventually on 6 October 1889, a judge ruled that Edison's electric light improvement claim for "a filament of carbon of high resistance" was valid. In 1893, Heinrich Göbel claimed he had designed the first incandescent light bulb in 1854, with a thin carbonized bamboo filament of high resistance, platinum lead-in wires in an all-glass envelope, and a high vacuum. Judges of four courts raised doubts about the alleged Göbel anticipation, but there was never a decision in a final hearing due to the expiration of Edison's patent. Research work published in 2007 concluded that the story of the Göbel lamps in the 1850s is fictitious. The main difficulty with evacuating the lamps was moisture inside the bulb, which split when the lamp was lit, with resulting oxygen attacking the filament. In the 1880s, phosphoric anhydride was used in combination with expensive mercury vacuum pumps. However, about 1893, Italian inventor Arturo Malignani (1865–1939), who lacked these pumps, discovered that phosphorus vapours did the job of chemically binding the remaining amounts of water and oxygen. In 1896 he patented a process of introducing red phosphorus as the so-called getter inside the bulb which allowed the production of economic bulbs lasting 800 hours; his patent was acquired by Edison in 1898.
== Major metabolic pathways converging on the citric acid cycle == Several catabolic pathways converge on the citric acid cycle. Most of these reactions add intermediates to the citric acid cycle, and are therefore known as anaplerotic reactions, from the Greek meaning to "fill up". These increase the amount of acetyl CoA that the cycle is able to carry, increasing the mitochondrion's capability to carry out respiration if this is otherwise a limiting factor. Processes that remove intermediates from the cycle are termed "cataplerotic" reactions. In this section and in the next, the citric acid cycle intermediates are indicated in italics to distinguish them from other substrates and end-products. Pyruvate molecules produced by glycolysis are actively transported across the inner mitochondrial membrane, and into the matrix. Here they can be oxidized and combined with coenzyme A to form CO2, acetyl-CoA, and NADH, as in the normal cycle. However, it is also possible for pyruvate to be carboxylated by pyruvate carboxylase to form oxaloacetate. This latter reaction "fills up" the amount of oxaloacetate in the citric acid cycle, and is therefore an anaplerotic reaction, increasing the cycle's capacity to metabolize acetyl-CoA when the tissue's energy needs (e.g. in muscle) are suddenly increased by activity. In the citric acid cycle all the intermediates (e.g. citrate, iso-citrate, alpha-ketoglutarate, succinate, fumarate, malate, and oxaloacetate) are regenerated during each turn of the cycle.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.